Key Points
- CEO Christopher Peetz sold 9,108 shares on Feb 2 at an average price of $103.30 for $940,856, leaving him with 160,294 shares (a 5.38% reduction in his position).
- Peetz also sold 6,831 shares on Jan 26 and 7,098 shares on Jan 22; the three sales total 23,037 shares for roughly $2.26 million, indicating sustained insider selling in recent weeks.
- Mirum shares are trading near their 52‑week high (~$105); the company recently beat EPS and revenue estimates with revenue up 47.1% year‑over‑year, and analysts carry an average target of $107.25 (average rating: Moderate Buy).
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) SVP Jolanda Howe sold 968 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $103.30, for a total transaction of $99,994.40. Following the completion of the transaction, the senior vice president directly owned 4,503 shares of the company's stock, valued at $465,159.90. This trade represents a 17.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Jolanda Howe also recently made the following trade(s):
- On Monday, January 26th, Jolanda Howe sold 842 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $96.19, for a total transaction of $80,991.98.
- On Thursday, January 22nd, Jolanda Howe sold 926 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $93.33, for a total transaction of $86,423.58.
Mirum Pharmaceuticals Stock Performance
Shares of MIRM opened at $105.45 on Wednesday. The company has a market cap of $5.42 billion, a price-to-earnings ratio of -122.61 and a beta of 0.49. The business's fifty day simple moving average is $81.60 and its two-hundred day simple moving average is $73.33. Mirum Pharmaceuticals, Inc. has a 12 month low of $36.88 and a 12 month high of $105.64. The company has a current ratio of 3.31, a quick ratio of 3.16 and a debt-to-equity ratio of 1.06.
Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The firm had revenue of $133.01 million for the quarter, compared to the consensus estimate of $130.11 million. During the same period in the prior year, the company posted ($0.30) earnings per share. The company's quarterly revenue was up 47.1% on a year-over-year basis. Research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of analysts have recently commented on MIRM shares. Raymond James Financial reiterated a "strong-buy" rating and issued a $110.00 price target on shares of Mirum Pharmaceuticals in a research note on Thursday, December 11th. Evercore ISI reaffirmed an "outperform" rating and issued a $101.00 target price on shares of Mirum Pharmaceuticals in a research report on Tuesday, January 20th. JMP Securities set a $95.00 price target on Mirum Pharmaceuticals in a report on Wednesday, November 5th. Leerink Partners set a $100.00 price objective on Mirum Pharmaceuticals in a report on Wednesday, December 10th. Finally, Citigroup reiterated an "outperform" rating on shares of Mirum Pharmaceuticals in a research report on Friday, December 19th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $107.25.
Read Our Latest Research Report on Mirum Pharmaceuticals
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the stock. Eventide Asset Management LLC increased its holdings in Mirum Pharmaceuticals by 4.4% in the 2nd quarter. Eventide Asset Management LLC now owns 2,637,485 shares of the company's stock worth $134,224,000 after acquiring an additional 110,485 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Mirum Pharmaceuticals by 2.0% in the fourth quarter. Vanguard Group Inc. now owns 2,596,089 shares of the company's stock worth $205,065,000 after purchasing an additional 50,720 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Mirum Pharmaceuticals by 6.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,029,616 shares of the company's stock valued at $52,405,000 after purchasing an additional 65,951 shares during the period. Wellington Management Group LLP raised its position in shares of Mirum Pharmaceuticals by 566.8% during the 3rd quarter. Wellington Management Group LLP now owns 790,689 shares of the company's stock valued at $57,965,000 after purchasing an additional 672,118 shares during the period. Finally, Boone Capital Management LLC lifted its stake in shares of Mirum Pharmaceuticals by 6.3% during the 2nd quarter. Boone Capital Management LLC now owns 641,448 shares of the company's stock valued at $32,643,000 after buying an additional 38,130 shares in the last quarter.
Mirum Pharmaceuticals Company Profile
(
Get Free Report)
Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.
Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
